Background: Patients with active cancer are often on chronic anticoagulation and frequently require interruption of this treatment for invasive procedures. The impact of cancer on periprocedural thromboembolism (TE) and major bleeding is not known.
introduction More than 2.5 million Americans are chronically anticoagulated for indications including venous thromboembolism (VTE), mechanical heart valve(s) (MHV) or atrial fibrillation (AF) [1] . Each year, ∼10 % of these patients require temporary interruption of anticoagulation for an invasive procedure. Defining the most appropriate management strategy for these patients requires an assessment of the periprocedural risk of thromboembolism (TE) and major hemorrhage. Cancer is associated with an increased risk of thrombosis and patients with cancer often require chronic anticoagulation [2] [3] [4] . Because these patients also frequently undergo invasive diagnostic or therapeutic procedures, providers frequently face the need for temporary interruption of anticoagulation therapy.
Although it is well known that cancer is associated with an increased risk of VTE [3] [4] [5] , it remains unclear whether the periprocedural risk of thrombosis is increased for cancer patients. It is also unclear whether cancer patients anticoagulated for other indications including MHV, AF or distal vascular graft preservation have an increased risk of periprocedural thrombotic events compared with noncancer patients. Patients with cancer also have increased risk of bleeding, particularly when anticoagulated. VTE patients with cancer have 2-to 3-fold increased risk of major bleeding compared with VTE patients without cancer [6, 7] . Frequent surgery, chemotherapy (often with the need of central line placement and associated cytopenias), hormone therapy, administration of multiple interacting drugs and varying dietary intake during the course of cancer therapy, all add to the complexity of anticoagulation management in cancer patients and particularly during invasive procedures. Despite the frequency with which we encounter this clinical situation, there is a paucity of data evaluating outcomes of patients with active cancer who require periprocedural anticoagulation. In a prospective protocol-driven study, the impact of active cancer on the periprocedural rate of thromboembolic and bleeding complication and overall survival during interruption of warfarin therapy was assessed compared with noncancer patients.
methods study population, design and setting
Consecutive chronically anticoagulated [warfarin or low-molecular weight heparin (LMWH)] patients who were referred to the Mayo Clinic Thrombophilia Center for periprocedural anticoagulation management over the 11-year period, 1 January 1997-31 December 2007, were eligible for inclusion; 97 % consented to participate. All patients were followed forward in time for 3 months from the date of the Thrombophilia Center consultation. Patients (or families members for deceased patients) who did not return for a clinic visit were mailed a questionnaire and/or contacted by telephone for any symptoms or signs of TE or bleeding in the 3 months after the Thrombophilia Center consultation and for vital status. The local medical records of patients reporting TE or bleeding and death certificates and autopsy reports for deceased patients were obtained and reviewed by the study end point adjudication committee. Two experienced study nurse abstractors reviewed and abstracted data from the complete inpatient and outpatient medical records for each patient. The study was approved by the Mayo Clinic Institutional Review Board.
Active cancer was defined as evidence of cancer identified by cross sectional imaging or as chemotherapy, radiation therapy or cancer-related surgery within the 3 months before Thrombophilia Center referral.
periprocedural anticoagulation management
All patients received recommendations on periprocedural anticoagulation management according to a standard protocol as previously described [8] . Patients typically were seen 4-7 days before the planned procedure. For patients requiring minor procedures associated with either a low risk of bleeding or easy access for physical hemostasis, the intensity of warfarin anticoagulation was reduced to the lower limit of the therapeutic range [international normalized ratio (INR) = 2.0] before the procedure. For those at low risk for arterial or venous TE, warfarin was stopped 4-5 days before the procedure and resumed as soon as possible afterward, starting with the patient's usual daily warfarin dose. For patients at high TE risk, warfarin was stopped 4-5 days before the procedure and i.v. unfractionated heparin or LMWH (bridging) therapy given when the INR was anticipated to fall below the lower limit of the therapeutic range (i.e. INR ≤ 2.0). To avoid any residual effect of heparin at the time of surgery, the last bridging LMWH subcutaneous injection was given 24 h before the procedure and at 50 % of the calculated once daily dose. When LMWH was restarted after the procedure, the first dose administration was delayed for 24 h in low-bleeding risk patients and for 48 h or longer if the period of high bleeding risk was prolonged. For patients bridged with unfractionated heparin, the i.v. infusion was stopped 6-8 h before surgery. Warfarin was usually restarted immediately after the procedure and overlapped with heparin for at least 5 days and until the INR exceeded the lower limit of the therapeutic range on at least two separate measurements carried out 24 h apart. Where feasible, aspirin and/or thienopyridine therapy was stopped 1 week before the procedure and restarted after the procedure when hemostasis was assured.
definition of study outcomes
The primary efficacy outcome was symptomatic venous or arterial TE occurring from 5 days before (the first day that warfarin was stopped) to 90 days after the procedure or surgery. VTE was defined as objectivelydiagnosed deep vein thrombosis or pulmonary embolism [9] . Arterial TE was defined as ischemic stroke, transient ischemic attack (TIA), amaurosis fugax, unstable angina, myocardial infarction or other peripheral artery TE. Criteria for unstable angina, myocardial infarction, stroke and TIA were those of the American Heart Association [10] . Peripheral arterial TE was defined as acute ischemia of an extremity or any organ other than the brain and arterial thrombus confirmed by either embolectomy or direct imaging.
The primary safety outcome was major bleeding. Major bleeding was defined as overt (visible) bleeding plus a hemoglobin decrease of ≥ 2.0 g/dl or transfusion of ≥ 2 U of packed red blood cells or intracranial, intraspinal, intraocular, retroperitoneal, pericardial or fatal bleeding [11] . All events were adjudicated using a priori criteria by a committee comprised of four Thrombophilia Center physicians blinded to patient name and health care provider.
statistical analyses
To determine whether active cancer was associated with arterial TE, VTE or major bleeding, we used SAS software. The outcomes were also analyzed according to the anticoagulation indication, divided into AF, MHV and VTE. For continuous variables, we used two-sample t-test to compare means. For categorical variables, we used the chi-square test for independence. The log-rank test was used to calculate P values in the survival plots (Kaplan-Meier curves). Based on prior reports, cancer types were stratified by thrombotic propensity. Cancer types deemed to be 'highly prothrombotic' included lymphoma, leukemia and renal, pancreatic, gastric and brain tumors [12] [13] [14] . Biopsies, endoscopy or endovascular interventional procedures were classified as 'low-bleeding risk procedures'.
results
During the 11-year study period, 2182 unique patients were referred to the Thrombophilia Center for periprocedural anticoagulation management of 2484 procedures (Table 1 ). Of these, 435 patients (20 % ) had active cancer. Two hundred and eleven patients underwent two procedures and 33 of these had active cancer. Thirty-nine patients had three or more procedures, 9 of these had active cancer at the time of their procedure. Nine procedures were carried out in patients receiving chronic LMWH only. One-fourth of cancer patients were receiving chemotherapy. Procedural numbers stratified by heparin 'bridging strategy' and cancer site are summarized in Figure 1 . Prostate (n = 95), gastrointestinal (n = 82) and urogenital (n = 61) cancers were the most frequent cancer sites. Cancers with high thrombosis risk represented 32 % of the cohort.
Patient demographic and clinical characteristics by cancer status are also provided in Table 1 . VTE, AF and MHV were the most common indications for chronic anticoagulation in both cancer and noncancer groups. Patients with cancer were significantly more likely to have VTE as an indication for chronic anticoagulation therapy. A minority of both groups had an alternate indication or multiple indications for anticoagulant therapy. Cancer patients were older and less frequently obese compared with noncancer patients. Noncancer patients had a significantly greater prevalence of congenital heart failure, hypertension, stroke/TIA and coronary artery disease. Cancer patients were more frequently anemic (hemoglobin <10) and less often treated with aspirin or lipidlowering medications.
The list of procedures for cancer patients stratified by procedure-specific bleeding risk is provided in Table 2 . Within the group of low bleeding risk, almost 30 % represented biopsies and 15 % endoscopies with biopsy. Within the moderate-to high-bleeding risk group, abdominal surgery comprised 19 % and urological procedures 13 % of procedures.
A similar small proportion of cancer (13%) and noncancer (16%) patients underwent minor procedures without warfarin interruption (Table 3) . Similar proportions of both groups received 'bridging' therapy with heparin. The duration of preprocedural warfarin interruption did not differ between the two groups. Cancer patients were started on heparin therapy more promptly before the procedure compared with noncancer patient. Following the procedure, warfarin reinitiation was delayed by ∼1 day longer for patients with active cancer.
The overall 3-month cumulative incidence of both arterial and venous TE complications was low (0.8 % ) and not significantly different in cancer compared with noncancer group (1.42 versus 0.65; P = 0.09). The rate of arterial TE was low (0.4 % ) and did not differ by cancer status ( Table 4 ). The overall venous thromboembolic rate was also low (0.4 % ) but significantly higher in cancer patients (1.2 % versus 0.2 % ; P = 0.001; Table 4 , Figure 2 ). Sixty percent of the VTE events occurred in cancer patients receiving chronic anticoagulation therapy for a prior VTE. Within the cancer group, the VTE rate did not differ by 'bridging strategy'.
The overall 3-month cumulative incidence of major bleeding was 2 % and significantly higher in cancer compared with noncancer patients (3.4 % versus 1.7 % ; P = 0.015). This difference was comprised of patients anticoagulated for either VTE (3.7 % versus 0.6 % ; P < 0.001) or 'other indications' (5 % versus 0.7 % ; P = 0.022; Table 4, Figure 3) . Moreover, among patients with cancer, the rate of major bleeding was higher if they received bridging heparin therapy (5 % versus 1 % ; P = 0.03). Bridging had no significant effect on the rate of bleeding among noncancer patients (2.0 % versus 1.1 % ; P = 0.17). Among cancer patients, the incidence of major bleeding did not differ by procedure-specific bleeding risk (low bleeding risk 3 % versus major bleeding risk 4 % ; P = 0.38).
The 3-month cumulative incidence for the composite of arterial and venous TE and major bleeding was 2.7 % and was higher among cancer patients compared with the patients without malignancy (4 % versus 2 % ; P = 0.01; Table 4 ). Patients who were anticoagulated because of VTE represented the only subgroup that had higher rate of composite outcome in active cancer patients compared with those without cancer (5 % versus 1 % ; P < 0.001).
Patients with cancer had significantly reduced 3-month survival compared with noncancer patients (95 % versus 99 % ; P < 0.001; Figure 4) . When analyzed by chronic anticoagulation indication, the cumulative 3-month survival was significantly reduced among cancer patients for all indications except MHV (Table 4, Figure 4 ). There were no fatal bleeding events. Survival was unaffected by bridging heparin therapy in the whole cohort (98.2 % versus 97.9 % ; P = 0.64) as well as in the group with active cancer (94.3 % versus 95.8 % ; P = 0.48).
The relationship between the specific cancer type and periprocedural outcomes is provided in Table 5 . The presence of a high-thrombosis risk cancer was not associated with the significant increased rate of VTE (2 % versus 1 % ; P = 0.53), arterial TE (1 % versus 0 % ; P = 0.20) or major bleeding (3 % versus 4 % ; P = 0.48).
Chemotherapy also was not associated with an increased rate of the VTE (2 % versus 1 % ; P = 0.15), arterial TE (1 % versus 0 % ; P = 0.08) or major bleeding (4 % versus 3 % ; P = 0.67).
discussion This is the first study to assess the impact of active cancer on periprocedural TE and bleeding rates among chronically anticoagulated patients. The main finding of this analysis is that patients with active cancer for whom anticoagulation was temporarily interrupted for an invasive procedure have significantly higher 3-month rates of VTE, major bleeding and death. These outcomes depend on the indication for anticoagulant therapy and were observed only for those cancer patients receiving anticoagulant therapy for prior venous thromboembolic events. Furthermore, LMWH bridging therapy during warfarin interruption resulted in higher bleeding rates without impacting recurrent TE events. For patients with AF or MHV, cancer status did not impact either thromboembolic or major bleeding outcomes. Cancer-related VTE therefore represents a complex clinical scenario particularly if an invasive procedure is necessary. While one of every five patients referred for periprocedural management of anticoagulation has active cancer, this percentage increases to 50 % if the indication for anticoagulation is prior VTE. In the RIETE registry, 20 % of patients with VTE had underlying cancer [15] . This is therefore a common scenario and management of these patients requires a careful balance between anticoagulation adjustment while preventing major bleeding complication. Although the association between active cancer and VTE is well established [2] [3] [4] [5] [6] [12] [13] [14] [15] , the impact on arterial TE risk is We had 493 procedures for patients with cancer but data on 491 procedures; one patient has no sufficient information on the type of procedure and the other had procedure canceled. Patients with cancer experienced a significantly higher rate of major bleeding compared with those without cancer (3 % versus 2 % ; P = 0.02) even though postoperative warfarin reinitiation in these patients occurred on average 1 day later. This difference was mainly due to cancer VTE group where the rate of major bleeding was 4 % . Bridging with heparin increased this rate to 5 % . These results are similar to those published in the RIETE registry (4.3 % ) during the first 3 months of anticoagulant initiation [7] . However, while onefourth of the patients who bled in RIETE registry died due to the bleeding event, we did not observe a lethal bleed in our cohort. Differences in cancer site, stage and treatment might explain some of the observed differences between our study and the RIETE registry. The impact of intensive medical care surrounding the recent procedure in our cohort may also have impacted survival. Our results are also similar to the CLOT trial, where the rate of major bleeding at 6 months was 4 % in the dalteparin arm and 6 % in the oral anticoagulant arm [16] . Moreover, the 3-month rate of anticoagulant complications observed in our cohort are similar to those reported by other registries or clinical trials of chronic anticoagulation [4, 5, 17] .
This periprocedural survival was significantly lower in cancer compared with noncancer patients (95 % versus 99 % ; P < 0.001). Survival was significantly lower in those cancer patients with VTE and with AF as an indication for anticoagulant therapy. However, survival among patients chronically anticoagulated for MHV was not significantly different among cancer compared with noncancer patients (Figure 3, Table 4 ). Furthermore, survival was not affected by LMWH bridging. original articles
Annals of Oncology
Several study limitations should be noted. First, the delivery of LMWH was not assigned randomly. Although careful patient stratification based on perceived risks and benefits of LMWH by the attending physicians may have contributed to low event rates, this scrutiny was provided for both cancer and noncancer patients. Similar rates of 'bridging' LMWH therapy was provided for patients irrespective of cancer status. Second, current guidelines recommend LMWH for Annals of Oncology original articles initial anticoagulation for VTE in patients with active cancer. In our cohort, only seven patients with cancer and two patients without cancer were treated with LMWH as their chronic anticoagulation therapy. The initiation of our study (1997) preceded the publication of the CLOT trial by 6 years. It was only the latter 3 years of the study where the preferential use of LMWH in cancer patients became apparent [7] . Currently, LMWH is offered to all cancer patients with newly diagnosed VTE in our clinic. A sizable percentage do not chose this treatment option and prefer warfarin therapy. Reasons include aversion to daily subcutaneous injections, renal failure, history of heparin induced thrombocytopenia and economic limitations. Moreover, it is our practice to offer LMWH to these patients for 3-6 months. Thereafter, these patients are converted to warfarin therapy despite the presence of active cancer. [4] [5] [6] [7] [12] [13] [14] [15] , we were unable to adjust for these covariates. As metastatic disease has been associated with incident VTE, future studies shall evaluate whether these patients may have a higher benefit from offering bridging.
conclusion
Patients with active cancer in whom anticoagulation was temporarily interrupted for an invasive procedure have higher 3-month rates of venous thromboembolism, major bleeding and death compared with the patients without active cancer. Malignancies considered to be of higher prothrombotic risk were not associated with the higher thrombotic risk. However, higher rates of venous TE and major bleeding were observed in patients with cancer who were anticoagulated for prior VTE episode(s). In these patients, LMWH use during warfarin interruption was associated with a higher risk bleeding but not with the lower rate of thromboembolic complications. A higher mortality rate was found in cancer patients treated with warfarin for VTE and for AF but not for MHV. Mortality was not affected by the use of LMWH. It is apparent that in patients with cancer, the outcomes of periprocedural interruption of anticoagulation depends on the indication for anticoagulation and it is clear that cancer patients anticoagulated for VTE are particularly vulnerable. 
